---
title: "Policy Pulse - Trump / US Watch - 16 Oct 2026"
ticker: "META:DJT:MRK:LLY:ABBV:VLO:PSX:F:NUE"
date: "2026-10-16"
tags: ["policy-pulse","us-only","russia","leader-trades","tariffs","fed"]
summary: "Two days from the Graham Act deadline there is still no Section 113(g) notice to Congress, leaving VLO, PSX and DAL on the right side of a licensed Russian diesel flow. Trump's pharma portfolio grew from $1.7 million to as much as $56.2 million as Medicare exemptions expanded, and the US-Mexico tariff deal stalled on the 25% auto and 50% metals levies."
model: "deepseek-v4-flash"
---

## Two Days From the Graham Act Deadline, and Still No Notice to Congress

The **Lindsey O. Graham Sanctioning Russia and Iran Act**, signed on **September 18, 2026**, sets **October 18** as the date by which the president must make his initial country determinations and impose the required measures. That is Sunday. Two days out, no target list, no rate and no waiver has been published.

- **Section 112** requires additional duties of **up to 500%** on Russian-origin goods, including petroleum products, stacked on existing duties.
- **Section 113** authorises duties of **up to 100%** on goods from countries among the five largest importers of Russian crude or natural gas — but only where those countries **knowingly make new purchases on or after October 18**. Purchases made before that date do not trigger it. India's exposure attaches only to future buying.
- The statute **directs the president to raise duties but specifies no numerical minimum for the initial rate**, and expressly excludes tariff authority over countries outside the listed categories. In other words, October 18 can be satisfied by a determination without a maximum-rate tariff landing.
- The **Section 113(g) notice to Congress**, on a ten-day clock, expired around **October 8** with nothing published.

On **October 16**, House Foreign Affairs chair **Michael McCaul**, **Jim Costa** and colleagues wrote to the administration urging "full and faithful" implementation by the first deadline, asking which countries will be hit, what trade and maritime data was used, and how exceptions for allies reducing their Russian purchases will be applied.

The contradiction at the centre of this is the diesel waiver. **OFAC General License 135 (October 9)** authorises Russian-origin diesel into the United States until **April 2027** — roughly **300,000 tonnes initially, 500,000 tonnes in November and 1 million tonnes thereafter**, about 6 million barrels, or roughly 1.5 days of US demand. Treasury Secretary **Bessent** rejected the claim that this bars the secondary tariffs. Representative **Krishnamoorthi** called it "illegal, ineffective" on October 15; Representative **Levin** cited an estimate near **$4 billion**.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| VLO, PSX, MPC | 🟢 Positive | ⚠️ inferred. US refiners with coastal and Gulf capacity are the physical counterparty for discounted Russian-origin barrels; a licensed diesel flow plus an unresolved secondary-tariff threat keeps the feedstock discount alive while capping the risk of a full embargo | 3/5 |
| XOM, CVX, COP | 🟡 Watch | ⚠️ inferred. Integrated majors are price-takers on the crude marker rather than the discount; the Graham Act matters to them through the Brent level that a Russian supply interruption would move, not through their own compliance | 2/5 |
| DAL, UAL, AAL, LUV | 🟢 Positive | ⚠️ inferred. Jet fuel is the largest controllable input cost for the airlines, and the OFAC licence specifically targets the distillate squeeze that fed the September PPI; a licensed diesel flow above 5% of daily US demand is a direct margin input for carriers | 2/5 |

## Trump's Pharma Portfolio Grew to $56.2 Million as Drugmakers Won Medicare Exemptions

The **Joint Economic Committee's minority staff** released a report on **October 16** tracking the president's pharmaceutical holdings against the Medicare price-negotiation carve-out that Republicans' 2025 tax and spending law expanded.

- Trump's reported pharmaceutical stock holdings grew **from a maximum value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025**.
- Of that, **up to $39.1 million sat in companies that benefited from exemptions** to Medicare's drug price negotiation programme — the expanded orphan-drug exclusion that delays or removes eligibility for negotiation.
- The portfolio **bought up to $2.55 million** of those beneficiaries' shares on **three dates before the legislation was signed in July 2025**, including **up to $950,000 on July 1, 2025** — the day the Senate passed the bill. It then bought **up to $1 million of AbbVie** in August 2025, after enactment.
- Through the **first eight months of 2026**, the portfolio continued trading pharma, adding **up to $3.5 million** of sector value.
- The report estimates Medicare beneficiaries on **Merck's Keytruda** and **Bristol Myers Squibb's Opdivo** could pay roughly **$5,000 more a year** than under negotiated pricing. Trump's portfolio holds both.

White House spokesperson **Davis Ingle** said the portfolio is independently managed by third-party institutions and denied any conflict of interest: "Neither President Trump nor any member of his family has any ability to direct, influence, or provide input regarding how the portfolio is invested." **Senator Maggie Hassan**, who leads the committee's minority arm, called the findings "outrageous and yet typical from this president."

This sits on top of the **August disclosure released on October 8**: **517 transactions** worth between **$74.3 million and $273.3 million**, including **up to $25 million of Meta bought on August 21**, **up to $5 million of SpaceX debt on August 18 — two days before the national security memorandum on commercial space transportation** — and same-day purchases of up to $5 million each of AT&T, ConocoPhillips, Abbott, Netflix and Chevron.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| MRK, BMY | 🟡 Watch | ✅ named. Both are named beneficiaries of the orphan-drug carve-out and both are in the disclosed portfolio; the JEC report is a political and reputational event, not a change in either company's cash flows | 3/5 |
| ABBV, LLY, PFE, JNJ, AMGN | 🟡 Watch | ⚠️ inferred. The Medicare negotiation exemption set is the whole large-cap pharma complex; a report that raises the political cost of the carve-out is the first live path to its reversal | 2/5 |
| META | 🟡 Watch | ✅ named. Up to $25 million in a single August session is the largest disclosed single-name position increase and creates a documented copy-trade reference point | 2/5 |
| DJT | 🔴 Negative | ⚠️ inferred. Every successive disclosure keeps the conflict-of-interest story in circulation, and the Truth API litigation has already converted a revenue catalyst into a legal overhang | 3/5 |

## The US-Mexico Tariff Deal Stalls on Autos and Metals

The one tariff file that had been moving is now the one that has stopped. The **Wall Street Journal** reported, and Reuters carried on **October 15**, that progress toward a US-Mexico deal that would cut US levies on **steel, aluminium and automobiles** in exchange for Mexican concessions has stalled.

- The blocker is **Commerce Secretary Howard Lutnick**, who opposed significant reductions in the **25% tariff on Mexican automobiles** and the **50% levies on steel and aluminium**, and objected to cuts on finished products made from them.
- Mexico's deputy trade minister **Luis Rosendo Gutierrez** nonetheless told the Journal there was progress in the negotiations, and a Commerce Department spokesperson said the department was in constant dialogue with Mexico.
- The practical read is that the metal and vehicle tariffs are now **policy objectives rather than negotiating chips**, which changes the arithmetic for every North American supply chain that had been waiting for relief.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| F, GM, STLA | 🔴 Negative | ⚠️ inferred. All three assemble in Mexico and had been pricing in a reduction of the 25% vehicle tariff; a stalled deal leaves the current landed cost in place through at least the next negotiating window | 3/5 |
| NUE, CLF | 🟡 Watch | ⚠️ inferred. Domestic steel producers are the beneficiaries of the 50% metals wall staying up, but they lose the volume certainty that a settled framework would have given their auto-facing order books | 2/5 |

## Warsh Calls AI the Most Consequential Change of His Lifetime — and the Hike Trade Unwinds

Speaking at the **IMF and World Bank gathering in Bangkok on October 16**, Fed Chair **Kevin Warsh** gave the AI complex an explicit endorsement: "I'd say the advent of this new technology is probably the most consequential change to the U.S. and the global economy in my lifetime. There really is, I think, a huge benefit to the global economy, the U.S. economy, over the horizon."

It is a striking intervention from a chair who has deliberately refused to signal policy, and it lands as the market has repriced the other way on rates.

- **October 27-28 hike odds have collapsed to roughly 13%** — CME FedWatch shows **87.3% hold against 12.7% hike**, and Kalshi prices 88% hold — down from the **~50%** priced after the hot September CPI on October 14.
- The **10-year Treasury yield has eased to about 5.07%**, and US equity funds drew renewed inflows as yields fell.

**The tape, stated properly.** Thursday **October 15** closed higher: **Dow +556.21 (+1.1%) to 52,177.69**, **S&P 500 +0.33% to 7,744.06**, **Nasdaq Composite +0.1%**, **Nasdaq 100 -0.05%**. Healthcare and financials led — **Eli Lilly +3.6%**, **Newmont +3.8%**. On **Friday October 16, at 8:43 a.m. ET, Dow futures were +41 (+0.08%), S&P 500 futures +10.5 (+0.13%) and Nasdaq 100 futures -59.75 (-0.20%)**; earlier in the session the Dow contract had been up 204 points. **Tesla rose 3.3-4.4% premarket** after unveiling a redesigned Roadster powered by rocket-style thrusters developed with **SpaceX**, which added 2.1%. **CoreWeave was down 2.5% premarket**, still the single most reliable barometer of AI financing stress. **US import prices rose more than expected in September**; industrial production and capacity utilisation for September are due later on Friday.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| LLY, NEM | 🟢 Positive | ✅ named. Both were the Dow's leaders on October 15 as capital rotated into healthcare and gold in the same session that the AI complex failed to hold its early gains | 3/5 |
| TSLA | 🟢 Positive | ✅ named. A product event with a SpaceX-branded propulsion story is a narrative re-rating, not an earnings one; the premarket move is real but the margin impact is not yet quantified | 3/5 |
| CRWV | 🔴 Negative | ✅ named. The debt-funded neocloud remains the transmission mechanism between AI sentiment and credit markets, and it was the only AI-linked name still falling in the premarket | 4/5 |
| NVDA, MU, AVGO, AMD | 🟡 Watch | ⚠️ inferred. The Warsh endorsement is a valuation support and the yield relief is a discount-rate support, but neither changes the financing conditions that produced the October drawdown | 3/5 |
| WMT, COST | 🟢 Positive | ⚠️ inferred. A falling 10-year with hike odds at 13% is the environment in which the defensive, low-beta, cash-generative retailer outperforms; it is the same trade that worked on October 15 | 2/5 |

## Oil, the IEA and the Diesel Dislocation

Oil is heading for a weekly gain, and the supply response is now explicit.

- The **IEA said on October 15** that its members agreed to release **the remaining roughly 100 million barrels** outstanding from its March pledge, in a timely manner, and that the total released would **exceed the original 400 million barrels** planned.
- **Brent fell 0.6% to $105.26 a barrel** and **WTI fell 0.9% to $97.11** on October 16, but both remain far above the **~$72** level of late February, before the Iran war began.
- ING strategists **Warren Patterson and Ewa Manthey** wrote that the market is "pricing in a significant risk premium" on Middle East supply and Strait of Hormuz flows.
- The **dollar index was 0.41-0.45% lower at 101.4-101.9**, which is itself a mild tailwind for dollar-denominated crude demand.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| XOM, CVX, OXY, EOG | 🟢 Positive | ⚠️ inferred. A coordinated strategic-stock release caps spikes but does not clear a war-risk premium of more than $30 a barrel against the pre-conflict baseline, which is a sustained cash-flow windfall for producers | 3/5 |
| VLO, PSX, MPC | 🟡 Watch | ⚠️ inferred. Refining margins depend on the crude-product spread, not the absolute crude price; a distillate-specific dislocation helps while a general crude decline compresses inventory value | 2/5 |
| DAL, UAL, AAL, LUV | 🟡 Watch | ⚠️ inferred. Ten days of Brent above $100 is a hedged-cost event for the majors and an unhedged one for the regionals, and the strategic release is the only mechanism currently working against it | 2/5 |

## What to Watch

- **October 18 (Sunday) / October 19** — the **Graham Act** first implementation deadline. The single document to watch is the **Section 113(g) notice to Congress**; without it no secondary tariff can lawfully attach on the deadline, and the shipping-vessel designation provisions in the interim carry no notice requirement at all.
- **October 19, 11:00 a.m. ET** — the advisory for a **Melania Trump-led executive order signing ceremony in the Rose Garden**, issued October 15.
- **October 22** — the **CBP de minimis compliance date** for partner-government-agency data and Chapter 98/99 consignments: low-value mail now carries fees, registration and a bond guarantee.
- **October 27-28** — **FOMC**. The hike has gone from a coin flip to roughly a one-in-eight chance in two sessions on the back of the AI-linked risk-off move.
- **November 3** — **US midterm elections**. The White House is already managing a leadership succession story, and the pre-election window constrains both tariff and strike decisions.
- **November 5** — the closed-door White House hearing at which DOJ officials may question Fed governor **Lisa Cook**.

---

*This is policy-impact analysis, not investment advice. Direction and confidence are stated so the reasoning can be checked; every position decision remains with the reader. Mappings marked ⚠️ inferred are deductions from the policy detail, not statements by the issuing authority. The October 16 US session was still open at the time of writing, so US index levels cited for October 16 are futures or premarket readings and the last completed close is October 15.*